Peer-Reviewed Publications

      Simulation of size-dependent aerosol deposition in a realistic model of the upper human airways

      Frederix, E. M. A.; Kuczaj, A. K.; Nordlund, M.; Bělka, M.; Lizal, F.; Jedelský, J.; Elcner, J.; Jícha, M.; Geurts, B. J.
      Published
      Oct 18, 2017
      DOI
      10.1016/j.jaerosci.2017.10.007
      Link to publication
      Topic
      Summary

      An Eulerian internally mixed aerosol model is used for predictions of deposition inside a realistic cast of the human upper airways. The model, formulated in the multi-species and compressible framework, is solved using the sectional discretization of the droplet size distribution function to accurately capture size-dependent aerosol dynamics such as droplet drift, gravitational settling and diffusion. These three mechanisms are implemented in a consistent way in the model, guaranteeing that the total droplet mass as given by the droplet size distribution is always equal to the total droplet mass due to the mass concentration fields. To validate the model, we simulate monodisperse glycerol aerosol deposition inside the lung cast, for which experimental data is available. Provided that an adequate computational mesh is used and an adequate boundary treatment for the inertial deposition velocity, excellent agreement is found with the experimental data. Finally, we study the size-dependent deposition inside the lung cast for a polydisperse aerosol with droplet sizes ranging from the nanometer scale to beyond the micrometer scale. The typical ‘V-shape’ deposition curve is recovered. The aim of this paper is to 1) provide an overview of the Eulerian aerosol dynamics model and method, to 2) validate this method in a relevant complex lung geometry and to 3) explore the capabilities of the method by simulating polydisperse aerosol deposition.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.